Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study

Wolfram Doehner, Johanna Todorovic, Cornelia Kennecke, Mathias Rauchhaus, Anja Sandek, Mitja Lainscak, Sophie Van Linthout, Carsten Tschöpe, Stephan Von Haehling, Stefan D. Anker

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Impaired insulin sensitivity is common in patients with chronic systolic heart failure (CHF) and contributes to symptomatic status and impaired prognosis. A specific metabolic effect to improve insulin sensitivity in diabetic patients has been reported for some but not all angiotensin II-receptor antagonists. We aimed to test the ancillary metabolic effect of irbesartan on insulin sensitivity in patients with CHF. Methods and participants: In this placebo-controlled double-blinded study 36 non-diabetic patients with stable ischemic CHF (age 63 ± 9 years, peak VO2 16.6 ± 4.8 ml/kg/min, LVEF 32 ± 9%) were randomized to irbesartan 300 mg/d vs placebo on top of standard CHF therapy. Body composition (dual energy X-ray absorptiometry), clinical status, peripheral vasodilator capacity (plethysmography) and neuroendocrine and metabolic profiles were assessed. Primary endpoint was the change of whole body insulin sensitivity after 4 months of treatment assessed by intravenous glucose tolerance testing and minimal modeling. Results: Insulin sensitivity improved by 26% (p <0.001) in the irbesartan group, but not in the placebo group (treatment effect: 1.044 min - 1·μU·ml- 1·104; 95%CI 0.45 to 1.64, p = 0.0026). Treatment effects on systolic and diastolic blood pressure were - 11 (95%CI - 21 to - 1) mm Hg and - 8 (95%CI - 15 to - 3) mm Hg, respectively. Peripheral vasodilator capacity improved by 14% (p = 0.016). Change in insulin sensitivity correlated with increased vasodilator capacity (R = 0.47, p = 0.021). Body composition and clinical status were not different after 4 months of therapy. Also adiponectin, resistin, cytokine profile, and asymmetric dimethylarginine (ADMA) were not changed after this short-term intervention. Conclusion: Therapy with irbesartan improved insulin sensitivity in patients with chronic heart failure. Improved peripheral vasodilator capacity may contribute to the metabolic effect. (Clinical trials identifier: NCT00347087).

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalInternational Journal of Cardiology
Volume161
Issue number3
DOIs
Publication statusPublished - Nov 29 2012

Keywords

  • Angiotensin receptor antagonist
  • Chronic heart failure
  • Endothelium function
  • Insulin sensitivity
  • PPAR gamma

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: A randomized double-blinded placebo-controlled study'. Together they form a unique fingerprint.

Cite this